|  Nederlands |  English |
 
 
12/11/2003: Janssen Animal Health Concludes Contract with Dechra Pharmaceuticals for the Distribution in Europe of the Veterinary Medicines Vetoryl® and Felimazole®.

Beerse, Dec. 12, 2003 – Janssen Animal Health, an affiliate of Janssen Pharmaceutica, has concluded a European marketing contract with Dechra Pharmaceuticals PLC, in Great Britain.

The five-year contract confers on Janssen Animal Health the marketing and distribution rights in Europe for the veterinary medicines Vetoryl® and Felimazole®, which were developed by Dechra Pharmaceuticals.

The two companies will initiate the European registration procedure jointly. They expect approval in the course of 2005. The products will remain the intellectual property of Dechra.

Vetoryl® is used to treat Cushing’s disease in dogs (tumors of the pituitary or the adrenal gland). This disease is one of the most frequent endocrinal disorders in dogs of all breeds, especially from the age of 7 years. Felimazole® is used to treat hypertrophy of the thyroid gland, the most frequent endocrinal disorder in cats.

Ian Page, Chief Executive of Dechra, commented as follows about the contract:
“The contract with Janssen Animal Health assures us of the knowledge of the market that is necessary to launch these products faster and more cost-effectively than we could do ourselves.”

And Pierre Scarceriaux, General Manager, Janssen Animal Health, Worldwide Business, had this to say:
“The contract adds two very interesting medicines to our portfolio and confirms that our company is recognized as a reference in the European market.”

Janssen Animal Health
Janssen Animal Health is a division of Janssen Pharmaceutica, which in turn belongs to the Johnson & Johnson group.
In most European countries and in South Africa, Janssen’s veterinary medicines are supplied by the selling organizations of Janssen Animal Health. In other countries, these medicines are distributed by authorized dealers.

Janssen Animal Health is renowned worldwide for its antiparasitic and antifungal products and also partners with other pharmaceutical companies for the sale of their products.

For more information, feel free to contact:
Guy Braem, Director Business Development
Janssen Animal Health
Tel: +32-(0)14-60 3282
www.janssenanimalhealth.com

 
Press Releases
12/12/2003 Janssen Animal Health Concludes Contract with Dechra Pharmaceuticals for the Distribution in Europe of the Veterinary Medicines Vetoryl® and Felimazole®.
11/12/2003 Flemish First Minister Bart Somers presents seven awards for the most innovative projects at Janssen Pharmaceutica
05/12/2003 Janssen Pharmaceutica Initiates Ambitious Diversity Policy
03/12/2003 Presentation of the Dr Paul Janssen Award for Pharmacology - 2002-200
01/12/2003 Janssen Pharmaceutica Geel wins ergonomics award
05/11/2003 The Plant and Material Protection Division of Janssen Pharmaceutica and Nongda develop in China sign production contract
24/10/2003 Janssen Pharmaceutica Saves Energy
06/06/2003 Annual results 2002: record investment in R&D and infrastructure promising new products
14/05/2003 Opening Clinical Pharmacology Unit
13/03/2003 Minister-President Patrick Dewael Lays Foundation Stone of New Building at Janssen Pharmaceutica
<< Back
 

 

 
© Janssen Pharmaceutica N.V., 1997-2009.

This site is published by Janssen Pharmaceutica NV and is intended for visitors from Europe. Use of the site constitutes your consent to application of European laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice.